Gene fusions of anaplastic lymphoma kinase (ALK) are common drivers in non–small-cell lung cancer that can be effectively treated with crizotinib. READ ARTICLE
Clinical Lung Cancer DOI:10.1016/j.cllc.2019.10.002
Authors: Marissa S. Mattar, Jason Chang, Ryma Benayed, Darragh Halpenny, Astin Powers, David E. Kleiner, Alexander Drilon, Mark G. Kris
